Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?, Published online: 28 June 2018; doi:10.1038/s41571-018-0055-6Following the success of poly(ADP-ribose) PARP inhibitors in patients with BRCA1/2 mutations, considerable research interest has emerged in the discovery of alternative forms of synthetic lethality. In this Review, the authors summarize the potential of various novel forms of synthetic lethality to further improve the treatment of patients with cancer.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research